New drug combo tested for Tough-to-Treat lung cancer
NCT ID NCT04524689
Summary
This study tested whether adding a new targeted drug called tusamitamab ravtansine to standard immunotherapy and chemotherapy could better control advanced lung cancer. It involved 57 adults with a specific type of non-small cell lung cancer that had spread and tested positive for a protein called CEACAM5. The main goals were to find safe doses and see if the new combinations could shrink tumors.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SQUAMOUS NON-SMALL-CELL LUNG CANCER (NSQ NSCLC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHRU BREST 5 Avenue Foch_Investigational Site Number :2500003
Brest, 29200, France
-
Centre François Magendie Hôpital du Haut Lévèque Av.de Magellan_Investigational Site Number :2500001
Pessac, 33600, France
-
Centro Avancado de Oncologia CECAN - Liga Contra o Cancer Site Number : 0760004
Natal, Rio Grande do Norte, 59062-000, Brazil
-
Centro de Investigacion y Desarrollo Oncologico (CIDO) Hochstetter 599 of. 602-603-1001, Temuco_Investigational Site Number :1520005
Temuco, La Araucanía, 4780000, Chile
-
Fakultní nemocnice Olomouc Onkologická klinika I.P. Pavlova 6_Site Number :2030001
Olomouc, 77900, Czechia
-
ICEGCLINIC Avenida Serafín Zamora 190 Torre B, piso 4. La Florida_Investigational Site Number :1520006
Santiago, 8241470, Chile
-
Institut Sainte-Catherine 250 Chemin de Baigne-Pieds_Investigational Site Number :2500005
Avignon, 84918, France
-
Investigational Site Number : 3760001
Ramat Gan, 5266202, Israel
-
Investigational Site Number : 3760002
Tel Aviv, 64239, Israel
-
Investigational Site Number : 7240001
Madrid, 28041, Spain
-
Investigational Site Number : 7240002
Las Palmas, 35016, Spain
-
Investigational Site Number : 7240004
Madrid, 28040, Spain
-
Investigational Site Number : 7240005
A Coruña, A Coruña [La Coruña], 15006, Spain
-
Investigational Site Number : 7240006
Badalona, Catalunya [Cataluña], 08916, Spain
-
Investigational Site Number : 7240007
Oviedo, Principality of Asturias, 33011, Spain
-
KU Medical Center_Investigational Site Number :8400002
Westwood, Kansas, 66205, United States
-
Nemocnice AGEL Ostrava - Vitkovice Plicní oddělení Zalužanského 2214/35_Site Number :2030002
Ostrava - Vitkovice, 70384, Czechia
-
ONCOCENTRO APYS Av. La Marina 1702, 2do piso, Viña del Mar_Investigational Site Number :1520003
Viña del Mar, Región de Valparaíso, 2520598, Chile
-
Orlandi Oncologia General Salvo 159, Providencia_Investigational Site Number :1520002
Santiago, 7500713, Chile
-
Országos Onkológiai Intézet Ráth György u. 7_Investigational Site Number :3480002
Budapest, 1122, Hungary
-
Pôle régional de Cancérologie 2 rue de la Milèterie BP 577_Investigational Site Number :2500004
Poitiers, 86021, France
-
Veszprém Megyei Tüdőgyógyintézet 049/2 Hrsz_Investigational Site Number :3480004
Farkasgyepü, 8582, Hungary
Conditions
Explore the condition pages connected to this study.